The Hypertrophic Cardiomyopathy Center at Stanford is specialized in the care of patients and families with hypertrophic cardiomyopathy (HCM) and other forms of familial cardiomyopathy. From the latest imaging techniques to sophisticated genetic profiling, our team offers world class care with an emphasis on compassion and communication.

At Stanford, we are proud of our team based approach and the Hypertrophic Cardiomyopathy Center offers interaction with genetic counselors, specialist nurses, cardiologists and cardiac surgeons. All are focused on giving you the best possible information to help clarify your diagnosis and maximize the treatment options available for you and your family.

Through close connections with the Cardiology Division of Lucile Packard Children’s Hospital, we facilitate care across generations. If required, we can even coordinate center visits for you and your children.

Although many patients with hypertrophic cardiomyopathy need little treatment and have a normal lifespan, certain patients have an increased risk of dangerous heart rhythms and sudden death. Fortunately, Stanford cardiologists, world leaders in the development of implantable cardioverter-defibrillator devices (ICDs), are available for advice, implantation of ICDs and after care.

For some patients, we may recommend surgery to remove thickened heart muscle or repair or replace valves. For this, we can turn to Stanford surgeons who were pioneers in the development of the myotomy-myectomy procedure for patients with hypertrophic cardiomyopathy.  

In addition, Stanford cardiologists were among the first to perform alcohol septal ablation, a less invasive technique to remove thickened heart muscle which many patients consider. Here at Stanford, we will help you make the best decision for your future care.

Hypertrophic Cardiomyopathy often affects young and athletic individuals. The Stanford Center has close links with the Stanford Sports Medicine division and maintains an active interest in athletes with cardiovascular abnormalities and the appropriate screening of athletes pre-participation.

Finally, we aim to define the future management of this disease. Stanford faculty are world renowned for research into the molecular genetics of cardiomyopathy. Many new diagnostic tools and therapies are developed here and Stanford patients are often among the first to benefit when new treatments come to clinical trials.

Normal Heart	Hypertrophic Cardiomyopathy